Navigation Links
Kantar Health Oncology Thought Leaders to Present at Upcoming Industry Meetings
Date:3/9/2010

NEW YORK, March 9 /PRNewswire/ -- Kantar Health, a leading healthcare-focused global consultancy and marketing insights company, today announced that two of its oncology thought leaders will be presenting their insights on market access and oncology target populations at upcoming oncology conferences.

Lee Blansett, Senior Vice President, will address how new rules and policy changes will affect pricing of oncology products and whether the new regulations will stifle innovation. Kevin Norell, Senior Vice President, will address how the expanding role of biomarkers could affect key business development decisions, particularly whether manufacturers can afford to pursue smaller subsegments of patients based on potential market forecasts.

Mr. Blansett will be a featured speaker at the 21st Annual Cancer Progress Conference, the hallmark conference for pharmaceutical and biotechnology executives, which will be held March 16-17, 2010, at the Hilton New York in New York City. Mr. Blansett's presentation is titled "Market Access Under Healthcare Reform." This presentation is recommended for senior executives concerned with market access and pricing for in-line and pipeline products targeting cancer and other severe diseases.

Mr. Blansett leads Kantar Health's U.S. market access practice and is deeply involved with the company's global market access practice. His engagements address commercial and public reimbursement, market access, government policy, managed care, and provider economics. His provider and plan experience includes current work with oncology medical groups and prior work with Stanford Medical Center, Kaiser Foundation Health Plans / The Permanente Medical Group, and APM.

Mr. Norell will be a featured speaker at eyeforpharma's Oncology USA Summit, which will be held March 23-24, 2010, at the Park Plaza Hotel in Boston. Mr. Norell will present "Insights into the New Reality: Do smaller target populations provide ROI?" on March 24 as part of the session "The Role of Biomarkers in Commercialization."

Mr. Norell leads Kantar Health's Advanced Applications and Modeling team, which provides new product forecasting and investment analysis, development of pro forma financials, and analysis of acquisitions and divestitures. He is a highly regarded modeler and an expert in the field of oncology forecasting. Before joining Kantar Health, Mr. Norell was an Operations Manager and Financial Analyst, analyzing financial operations and valuations of acquisition candidates.  

For the sixth consecutive year Kantar Health is a major sponsor of the Cancer Progress Conference.

Kantar Health is a Global Sponsor for Oncology USA Summit.

About Kantar Health

Kantar Health is a leading healthcare-focused global consultancy, specializing in portfolio optimization, market access, safety and outcomes, and brand and customer insights Formed by uniting Consumer Health Sciences, MattsonJack, TNS Healthcare and Ziment, it is the next-generation decision support partner to the pharmaceutical and biotech industries, delivering evidence-based guidance to support clients' global and local success.

With 40+ offices throughout the Americas, Europe, Asia-Pacific, the Middle East and Africa, Kantar Health provides the broadest global footprint, coupled with the strongest local knowledge to help drive clients' maximum performance in every geography. Market-leading solutions ensure optimal decisions and actions across the brand life cycle, from assessing opportunities and sizing markets…to developing products and building access strategies…to positioning brands and creating messaging…to managing stakeholder relationships and monitoring treatment outcomes.

SOURCE Kantar Health

Back to top

RELATED LINKS
http://www.kantarhealth.com

'/>"/>

SOURCE Kantar Health
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
4. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Tone Deafness Explained, from the Harvard Health Letter
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
9. ViroPharma to Present at Three Upcoming Healthcare Conferences
10. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 2016 Global Paclitaxel Market 2016 ... 12 companies and the Paclitaxel analysis in this study ... industry and its players. This is the ... details the current state of the industry while providing ... applications and industry chain structure. The Paclitaxel market analysis ...
(Date:5/23/2016)... May 23, 2016 According ... Share, Development, Growth and Demand Forecast to 2022 ... Other), by Application (Drug Discovery and Development, Proteomics, ... (Pharmaceuticals, Life Science and Biotechnology, Academic and Research ... Research, the global mass spectrometry market ...
(Date:5/23/2016)... , May 23, 2016 ... for detection of multiple diseases; ,Technology to be presented ... Yissum Research Development Company of the Hebrew ... into a research agreement with Aurum Ventures MKI, the technology ... development of a new diagnostic approach for early detection ...
Breaking Medicine Technology:
(Date:5/24/2016)... , ... May 24, 2016 , ... How to Write ... Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major ... human error will ever be totally eliminated, many human performance problems can be prevented. ...
(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health (LLUH) has officially broken ... Children’s Hospital. Over 3,000 people looked on as the shovels hit the dirt at ... slidehsow. , During the program, Richard H. Hart, MD, DrPH, president, LLUH, recapped ...
(Date:5/24/2016)... ... May 24, 2016 , ... Eggsurance, ... the official relaunch of its community and education hub for women considering fertility ... is to create a safe and welcoming place for women to find cycle ...
(Date:5/24/2016)... ... May 24, 2016 , ... Tuesday, May 24, Women's Excellence in Wellness, powered ... Young Living Essential Oils, taught by Patti Dolan, RYT, a Young Living Gold ... Flow is 6:30pm - 7:15pm followed by a small intro to the Oils that ...
(Date:5/24/2016)... ... May 24, 2016 , ... In light of recent heavy flooding in Houston, ... contaminated well water throughout the Houston area. , Heavy floodwaters have led to destroyed ... to contaminants. Residents may not even be aware of the contamination of their water ...
Breaking Medicine News(10 mins):